Research

RET inhibitor and chemotherapy treatment for lung cancer

Research Treatment

Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients

RET Inhibitor with chemotherapy after progression may improve outcomes for RET lung cancer patients

Irene Guijarro MunozJuly 10, 2026

Research

New FOXM1 T cell therapies that can target RET tumors

Researchers at MD Anderson Cancer Center have found that RET lung cancers have unusually high…

Irene Guijarro MunozJune 24, 2026

Research

What the New NCCN Guidelines Mean for RET+ Lung Cancer

The recent NCCN Guideline update represents an important advancement in the treatment of early-stage NSCLC.

Irene Guijarro MunozJune 19, 2026

Research

RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)

The ASCO Annual Meeting 2026, held in Chicago, brought together oncology experts, researchers, healthcare professionals,…

Irene Guijarro MunozJune 12, 2026

Research

ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer

Results support the use of selpercatinib in the early-stage setting and highlight the need for…

Irene Guijarro MunozJune 3, 2026

2026 AACR annual meeting RET cancer findings

Research

New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC

New research from the 2026 AACR Annual Meeting shows that certain co-mutations and fusion partners…

Irene Guijarro MunozMay 27, 2026

asco 2026 annual meeting RET feature presentations

Education Research

RET Cancer Research Takes Center Stage at ASCO, May 2026

The 2026 ASCO Annual Meeting 2026, taking place May 29–June 2 in Chicago, will feature…

Irene Guijarro MunozMay 15, 2026

Education Research

Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026

Join the special edition of Together Separately, presented by LCRF and the Susan Wojcicki Foundation…

Irene Guijarro MunozApril 30, 2026

Clinical Trials Research Treatment

BioNTech’s BNT116 mRNA cancer vaccine trial has opened a new RET cohort

Exciting news for the RET community! BioNTech’s BNT116 mRNA cancer vaccine trial now enables combination…

Irene Guijarro MunozApril 27, 2026

ARROW clinical trial ret lung cancer findings

Clinical Trials Research

Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results

The findings confirm what many in the RET+ community have been hoping to see: durable…

Irene Guijarro MunozApril 24, 2026

Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients

New FOXM1 T cell therapies that can target RET tumors

What the New NCCN Guidelines Mean for RET+ Lung Cancer

RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)

ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer

New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC

RET Cancer Research Takes Center Stage at ASCO, May 2026

Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026

BioNTech’s BNT116 mRNA cancer vaccine trial has opened a new RET cohort

Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results

Popular Posts

Scientific research can be confusing and overwhelming